Clinical trial
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With…
NCT00110149 · Beth Israel Deaconess Medical Center, Other · Terminated
Key facts
| NCT number | NCT00110149 |
|---|---|
| Title | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as First Line Treatment in Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | rituximab, yttrium Y 90 ibritumomab tiuxetan |
| Enrollment | 12 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2012 |
| Completion | Mar 1, 2015 |
| First posted | May 4, 2005 |
| Last update posted | Nov 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: